Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Eye Contact Lens. 2019 Jan;45(1):11–18. doi: 10.1097/ICL.0000000000000544

Figure 1.

Figure 1

Examples of ocular surface disease in glaucoma patients poorly-tolerant to topical antiglaucomatous drops A) Evidence of telangiectatic vessels at lid margin, matting of lashes, and meibomian gland disease after separate trials of brimonidine tartrate/timolol maleate 0.2%/0.5%, latanoprost 0.005%, bimatoprost 0.01%, timolol 0.5% B) Diffuse punctate epithelial erosions under fluorescein staining in a patient on bimatoprost 0.01%, brimonidine tartrate 0.1%. C) Diffuse conjunctival hyperemia in a patient on travoprost 0.004% D) Diffuse conjunctival injection and subepithelial haze from persistent epitheliopathy after taking multiple BAK-containing glaucoma drops, including brimonidine tartrate/timolol maleate 0.2%/0.5%